News & Events

Pharmaceutical Research on a tablet
Featured

Cerium Pharmaceuticals receives FDA Orphan Drug Designation for Corticotropin (ACTH) porcine (synthetic) for the treatment of Membranous Nephropathy

Cerium Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation (ODD) for Corticotropin (ACTH) porcine (synthetic), otherwise referred to as SNP-ACTH (1-39) Gel. This investigational agent is in development for the treatment of primary membranous nephropathy (PMN) a rare kidney disease that affects approximately

Read More »
Featured

Closing of our Series B investment

Cerium Pharmaceuticals, Inc., a clinical stage biopharmaceuticals company focused on developing medicines for rare and orphan diseases, today announced that it has closed a $12 million Series B financing.

Read More »